DILANTIN

Compare DILANTIN  to:
Compare
Compare

Generic Name for DILANTIN

Phenytoin sodium 30mg, 100mg; ext-rel caps.

Legal Classification:

Rx

Pharmacological Class for DILANTIN

Hydantoin.

Manufacturer of DILANTIN

Pfizer Labs

Indications for DILANTIN

Tonic-clonic, psychomotor and neurosurgically induced seizures.

Adult dose for DILANTIN

Initially: 100mg 3 times daily. Increase weekly if needed; max 200mg 3 times daily. Once-a-day dosing only with ext-rel caps for patients controlled on 300mg daily.

Children's dosing for DILANTIN

Initially 5mg/kg per day in 2–3 equally divided doses. Increase weekly if needed. Usual maintenance: 4–8mg/kg per day; max 300mg daily.

Also:

Warnings/Precautions for DILANTIN

Diabetes. Impaired liver function. Change dose gradually. Discontinue if rash develops. Monitor serum levels. Use proper dental hygiene. Hormonal contraception. Porphyria. Elderly. Debilitated. Pregnancy. Nursing mothers: not recommended.

Interactions for DILANTIN

Potentiated by acute alcohol ingestion, amiodarone, benzodiazepines (eg, diazepam), chloramphenicol, dicumarol, disulfiram, estrogens, fluoxetine, halothane, H2 blockers, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinamides (eg, ethosuximide), sulfonamides, tolbutamide, trazodone, others. Antagonized by chronic alcohol ingestion, carbamazepine, reserpine, others. Antagonizes tricyclic antidepressants, oral anticoagulants, oral contraceptives, estrogens, corticosteroids, doxycycline, digitoxin, furosemide, theophylline, rifampin, quinidine, vitamins D and K, others. Variable effects with phenobarbital, valproic acid, divalproex, others. Absorption decreased by calcium, antacids.

Adverse Reactions for DILANTIN

Nystagmus, ataxia, slurred speech, decreased coordination, dizziness, GI disturbances, gingival hyperplasia, osteomalacia, blood dyscrasias, lymphadenopathy, hepatic disease, rash, hyperglycemia, SLE, hypertrichosis.

How is DILANTIN supplied?

Caps, Tabs—100
Susp—8oz

Related Disease:

Epilepsy
Seizure disorders

Related Resources

Phase 3 study of perampanel for the treatment of epilepsy

August 24, 2010

Eisai announced results from its Phase 3 study of perampanel for the treatment of partial seizures in patients with epilepsy.

FDA warns of aseptic meningitis risk with Lamictal

August 13, 2010

The FDA has informed healthcare professionals and patients that Lamictal (lamotrigine, from GlaxoSmithKline) can cause aseptic meningitis.

Oral solution formulation of Vimpat available

June 14, 2010

UCB announced that it has made available an oral solution formulation of Vimpat (lacosamide), an antiepileptic drug for the add-on treatment of partial-onset seizures in patients ≥17 years of age with epilepsy.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Lamictal XR approved as add-on therapy for primary generalized tonic-clonic seizures

February 01, 2010

The FDA has approved Lamictal XR (lamotrigine extended-release tablets, from GlaxoSmithKline) as a once daily, add-on therapy for epilepsy in patients ≥13 years of age with primary generalized tonic-clonic seizures.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions